Evidence map›Paper›PMID 27941156›Full record

SynthesisGut2017

Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis.

Daniel de la Iglesia-García, Wei Huang, Peter Szatmary, Iria Baston-Rey, Jaime Gonzalez-Lopez, Guillermo Prada-Ramallal, Rajarshi Mukherjee, Quentin M Nunes, J Enrique Domínguez-Muñoz, Robert Sutton and 1 more

2 registry-linked trialsOpen access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Gut, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 84 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 7 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05480241 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Impact of Exocrine Pancreatic Insufficiency Associated With Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy on Gut Microbiota, Immunological Changes and Quality of Life

TypeinterventionalSponsorUnidade Local de Saúde de Coimbra, EPERan2022 to 2024Enrolled84ConditionsAcute Pancreatitis, Exocrine Pancreatic Insufficiency, Gut Microbiota, ImmunologyArmsPancreatic Enzyme Replacement Therapy, Placebo
NCT07697352 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomised, Double-Blind, Non-Inferiority Trial Comparing Microbial and Porcine Pancreatic Enzyme Replacement Therapy in Chronic Pancreatitis

TypeinterventionalSponsorAsian Institute of Gastroenterology, IndiaRan2026 to 2027Enrolled134ConditionsPancreatitis, Chronic, Exocrine Pancreatic Insufficiency (EPI)ArmsDietary Supplement: Pancreatic enzyme preparation from microbial source that contains amylase (6650 DU), lipase (13000 FIP), and protease (7120 HUT, 15 SAPU, 3000 PC)., Standard of care porcine pancreatic enzyme preparation: amylase (8000 U), lipase (25000 U), and protease (1000 U)
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 7 syntheses or guidelines pooled it, 193 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Guideline
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Observational
  10. Pancreatic exocrine insufficiency beyond pancreatitis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Review
  11. Article
  12. Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026
    Article
  13. Clinical Practice Update on the Evaluation, Diagnosis, and Management of Pancreatic Exocrine Insufficiency: Expert Review.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026
    Review
  14. Pancreatic exocrine insufficiency.EClinicalMedicine · 2026
    Review
  15. Article
  16. Review
  17. Idiopathic chronic pancreatitis: clinical highlights.Therapeutic advances in gastroenterology · 2026
    Review
  18. Article
  19. Review
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Daniel de la Iglesia-GarcíaNIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK.
Wei HuangNIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK.
Peter SzatmaryNIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK.
Iria Baston-ReyDepartment of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Compostela, Spain.
Jaime Gonzalez-LopezDepartment of Pharmacy, University Hospital of Santiago de Compostela, Compostela, Spain.
Guillermo Prada-RamallalDepartment of Preventive Medicine and Public Health, University of Santiago de Compostela, Compostela, Spain.
Rajarshi MukherjeeNIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK.
Quentin M NunesNIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK.
J Enrique Domínguez-MuñozDepartment of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Compostela, Spain.
Robert SuttonNIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK.ORCID 0000-0001-6600-562X
NIHR Pancreas Biomedical Research Unit Patient Advisory Group
University of Liverpool · GBUniversidade de Santiago de Compostela · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe benefits of pancreatic enzyme replacement therapy (PERT) in chronic pancreatitis (CP) are inadequately defined. We have undertaken a systematic review and meta-analysis of randomised controlled trials of PERT to determine the efficacy of PERT in exocrine pancreatic insufficiency (EPI) from CP.

designMajor databases were searched from 1966 to 2015 inclusive. The primary outcome was coefficient of fat absorption (CFA). Effects of PERT versus baseline and versus placebo, and of different doses, formulations and schedules were determined.

resultsA total of 17 studies (511 patients with CP) were included and assessed qualitatively (Jadad score). Quantitative data were synthesised from 14 studies. PERT improved CFA compared with baseline (83.7±6.0 vs 63.1±15.0, p<0.00001; I

conclusionsPERT is indicated to correct EPI and malnutrition in CP and may be improved by higher doses, enteric coating, administration during food and acid suppression. Further studies are required to determine optimal regimens, the impact of health inequalities and long-term effects on nutrition.

Indexed as

Enzyme TherapyDietary FatsEnzymesExocrine Pancreatic InsufficiencyFecesHumansNutritional StatusPancreasPancreatitis, ChronicQuality of LifeRandomized Controlled Trials as TopicDietary FatsEnzymesEXOCRINE PANCREATIC FUNCTIONNUTRIENT ABSORPTIONPANCREATIC ENZYMESPANCREATITIS

Identifiers

PMID27941156
PMCPMC5530474
OpenAlexW2560155202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.